Skip to content

High Frequency Chest Wall Oscillations Versus Lung Flute in Chronic Obstructive Pulmonary Disease Post(SARS-CoV-2)

Efficacy of High Frequency Chest Wall Oscillations Versus Lung Flute in Chronic Obstructive Pulmonary Disease Postcovid

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05591781
Enrollment
60
Registered
2022-10-24
Start date
2022-10-31
Completion date
2022-12-31
Last updated
2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Brief summary

COPD causes an acute deterioration of respiratory symptoms, particularly increased breathlessness and cough, and increased sputum volume and/or purulence. Worsening airflow limitation is associated with an increasing prevalence of exacerbations and risk of death. These exacerbations can range from self-limited diseases to episodes of florid respiratory failure requiring mechanical ventilation .Hospitalization for COPD patients post COVID is associated with poor prognosis with increased risk of death. Hence techniques of efficient clearance of peripheral airways may reduce airway occlusion by excess mucus and inflammatory cells, improving lung function, exercise capacity and reducing exacerbation frequency.

Detailed description

Patients were assigned to 2 groups with pre- and post- treatment protocol application. All patients were thoroughly evaluated before and after treatment protocol application. Thirty patients (Group A) received high frequency chest wall oscillation with vest system in addition to their prescribed medication, 3 times per week for three successive weeks and the total duration of each session was 15-30 minutes. Thirty patients (Group B) received Lung flute (OPEP) in addition to their prescribed medication, 2 times per week twice a day for three successive weeks and the total duration of each session was 10-15 minutes

Interventions

DEVICEhigh frequency chest wall oscillation with vest system

Patients were assigned to 2 groups with pre- and post- treatment protocol application. All patients were thoroughly evaluated before and after treatment protocol application.

DEVICELung flute (OPEP)

. Thirty patients (Group B) received Lung flute (OPEP) in addition to their prescribed medication, 3 times per week twice a day for three successive weeks

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
40 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* All patients aged 40-60 years old * All patients were recovered from COVID not more than 3 months * All patients were diagnosed as COPD for at least two years ago. * All patients had irreversible/ partially reversible obstruction of airflow. * COPD patients had a post-bronchodilator, FEV1/FVC% \< 70%. They had an increase in FEV1\< 200 ml, or \< 12% of baseline value 20 minutes after 2 puffs of inhaled salbutamol (100 µg) given via a metered-dose inhaler.

Exclusion criteria

* Presence of malignant disease. * Patients with acute infection. * History of osteoporosis, significant gastro-oesophageal reflux, hiatus hernia. * Recent acute cardiac event (6 weeks) or congestive cardiac failure. * Any significant musculoskeletal disorders.

Design outcomes

Primary

MeasureTime frameDescription
Forced vital capacity (FVC)Forced vital capacity (FVC)will be measured at baseline, and after three weeks.FVC is the amount of air that can be forcibly exhaled from lungs after deepest inspiration, it's measured by spirometry
Forced expiratory volume in one second (FEV1)FEV1 will be measured at baseline, and after three weeks.FEV1 is the maximum amount of air that the subject can forcibly expel during the first second following maximal inhalation
FEV1/FVC ratioFEV1/FVC ratio will be measured at baseline, and after three weeks.The FEV1/FVC is a ratio that reflects the amount of air you can forcefully exhale from your lungs. It's measured by spirometry, a test used to evaluate lung function
The forced mid-expiratory flow (FEF25-75%)(FEF25-75%) will be measured at baseline, and after three weeks.(FEF25-75) measures the average flow rates of medium-to-small airways during the forced vital capacity (FVC).it' is a potentially sensitive marker of obstructive peripheral airflow

Secondary

MeasureTime frameDescription
Six-minute walk test6min walk test will be measured at baseline, and after three weeks.Six-minute walk test was carried out before and after interventions to determine the patient functional capacity
COPD assessment test (CATCOPD assessment test (CAT)will be measured at baseline, and after three weeks.is a validated, short (8-item) and simple patient completed questionnaire

Countries

Egypt

Contacts

Primary ContactAlaa El-Moatasem, lecturer
alaamotasem@rocketmail.com01006625054
Backup ContactOmnia Ahmed, Lecturer
omsaeed@msa.edu.eg01227805225

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026